The administration of drugs to the central nervous system (CNS) is primarily controlled by
the blood-brain barrier (BBB), a structure that prevents the passage of foreign compounds …

The main limitation to the success of central nervous system (CNS) therapies lies in the
difficulty for drugs to cross the blood–brain barrier (BBB) and reach the brain. Regarding its …

The management of the central nervous system (CNS) disorders is challenging, due to the
need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the …

In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

Nose-to-brain drug delivery has been of great interest for the treatment of many central
nervous system (CNS) diseases and psychiatric disorders over past decades. Several …

Nose to brain drug delivery is considered as a viable option to deliver various therapeutic
agents with low cerebral bioavailability bypass blood-brain barrier (BBB). The drug …

The nasal route has been used for many years for the local treatment of nasal diseases.
More recently, this route has been gaining momentum, due to the possibility of targeting the …

Scientific research has focused its attention on finding an alternative route to systemic oral
and parenteral administration, to overcome their usual drawbacks, such as hepatic first-pass …

Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous
system's structure and function due to oxidative stress, mitochondrial dysfunction, protein …

Solid-lipid nanoparticles (SLNs) are an innovative group of nanosystems used to deliver
medicine to their respective targets with better efficiency and bioavailability in contrast to …